Half-dose for Halcygen

By Dylan Bushell-Embling
Tuesday, 07 October, 2008

Halcygen Pharmaceuticals (ASX: HGN) has demonstrated the effectiveness of the company's SUBA-itraconazole antifungal in a recent pharmacokinetic trial.

The trial was the first of three pharmacokinetic studies the company is conducting for the Investigational New Drug [IND] application recently approved by the FDA.

Halcygen was able to prove that SUBA-itraconazole in a 'half-dose' format gives comparable pharmacokinetic levels to a full dose of itraconazole market leader Sporanox.

All three pharmacokinetic trials should be complete by the end of the year.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd